沙利文授予药明康德2026年沙利文全球CRDMO年度公司奖
沙利文授予药明康德2026年沙利文全球CRDMO年度公司奖
Frost & Sullivan awards SULLIVAN China the '2026 Frost & Sullivan Global CRDMO Annual Company Award'.
关于药明康德
公众号名称
Frost & Sullivan awards WuXi AppTec with 2026 Global Company of the Year Recognition for CRDMO Leadership
SAN ANTONIO, Oct. 20, 2026 – Frost & Sullivan has awarded WuXi AppTec the 2026 Global Company of the Year Recognition in the CRDMO industry for its strong performance in enabling innovation, operational excellence, and customer impact.
Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. WuXi AppTec excelled in both: its integrated CRDMO model offers broad capabilities, global manufacturing capacity, and quality management across the full drug development cycle, supported by a network across Asia, Europe, and North America that maintains flexibility and operational resilience.
“WuXi AppTec distinguishes itself through its strong focus on evolving customer needs,” said Unmesh Lal, Vice President, Healthcare and Life Sciences at Frost & Sullivan. “Its commitment to customer success reinforces its position as a trusted partner to biopharmaceutical innovators worldwide.”
“We are honored that Frost & Sullivan has once again recognized what our teams deliver every day for customers,” said Dr. Ge Li, Chairman and CEO of WuXi AppTec. “As a dedicated enabler of the pharmaceutical industry, we will remain committed to our CRDMO strategy, helping customers bring life-changing therapies to market faster and benefit patients around the world.”
Innovation is core to WuXi AppTec’s growth strategy. The company therefore continuously invests in its development and manufacturing capabilities for emerging therapeutic modalities and advanced technologies, including oligonucleotides, peptides and related conjugated medicines. These investments enhance lead candidate optimization and accelerate development efficiency.
WuXi AppTec’s operational excellence extends to quality and regulatory compliance. In 2025 alone, the company completed 741 regulatory inspections and customer audits with zero critical findings. Its One Global Quality System supports standardized governance and quality practices across operating locations, while integrated project management enables teams to address complex technical and regulatory challenges efficiently.
Each year, Frost & Sullivan presents the Global Company of the Year Recognition to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market position, customer value, and competitive strength. The recognition highlights forward-thinking organizations that are shaping their industries through innovation and growth excellence.
About WuXi AppTec
WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time.
推荐阅读
▸沙利文授予珍奥集团2026年沙利文全球5'-核苷酸技术创新领导奖
▸沙利文授予极巡科技2026年沙利文全球智能电动三轮车行业技术创新领导奖
▸沙利文授予杰华生物2026年沙利文全球大分子新药技术创新领导奖
▸沙利文授予凌科药业2026年沙利文全球自免及炎症小分子新药年度公司奖
▸沙利文授予青民数科2026年沙利文中国AI保险技术创新领导奖
▸沙利文授予未岚大陆 2026年沙利文中国无边界割草机器人年度公司奖
▸沙利文授予广州派真生物2026年沙利文全球基因疗法CRDMO技术创新领导奖
▸沙利文授予酶好生活集团2026年沙利文全球酶基产品技术创新领导奖
* 以上内容系沙利文研究团队基于市场研究得出,系团队研究成果的公示,研究所使用的部分信息来源于公开资料。如您对本次研究的结果有疑义,欢迎发送邮件至:PR@frostchina.com 咨询。



